Intratumoral Ral-binding Protein 1 (RalBP1) Expression as a potential Predictor of the Efficacy of Bevacizumab Therapy in Female Patients with Ovarian Cancer

被引：0
|
作者：
Schramm, C. [1 ]
Kraus, F. [1 ]
Mayr, D. [2 ]
Chelariu-Raicu, A. [1 ]
Reichenbach, J. [1 ]
Topalov, N. E. [1 ]
Tauber, C. [1 ]
Burges, A. [1 ]
Kessler, M. [1 ]
Mahner, S. [1 ]
Trillsch, F. [1 ]
Czogalla, B. [1 ]
机构：
[1] LMU Munchen, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany
[2] LMU Munchen, Pathol Inst, Munich, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1055/s-0044-1787409
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P10
引用
收藏
页码：E42 / E42
页数：1
相关论文
共 50 条
  • [1] Intratumoral Ral-binding protein 1 (RalBP1) expression as a potential predictor of bevacizumab treatment efficacy in patients with ovarian cancer
    Kraus, Fabian Bernhard Thaddaeus
    Schramm, Christina
    Mayr, Doris
    Chelariu-Raicu, Anca
    Reichenbach, Juliane
    Topalov, Nicole Elisabeth
    Tauber, Christina Viktoria
    Burges, Alexander
    Kessler, Mirjana
    Mahner, Sven
    Trillsch, Fabian
    Czogalla, Bastian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] RalBP1, a novel approach for ovarian cancer therapy
    Singhal, Sharad S.
    Ramisetty, Sravani
    Mohanty, Atish
    Kulkarni, Prakash
    Horne, David
    Awasthi, Sanjay
    Salgia, Ravi
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76)
    Herlmen, Mikael C.
    Theodorescu, Dan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 362 (01) : 56 - 62
  • [4] IDENTIFICATION AND CHARACTERIZATION OF RAL-BINDING PROTEIN-1, A POTENTIAL DOWNSTREAM TARGET OF RAL GTPASES
    CANTOR, SB
    URANO, T
    FEIG, LA
    MOLECULAR AND CELLULAR BIOLOGY, 1995, 15 (08) : 4578 - 4584
  • [5] Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1)
    Singhal, Sharad S.
    Singhal, Jyotsana
    Yadav, Sushma
    Dwivedi, Seema
    Boor, Paul J.
    Awasthi, Yogesh C.
    Awasthi, Sanjay
    CANCER RESEARCH, 2007, 67 (09) : 4382 - 4389
  • [6] HIF-1 alpha expression as a predictor of bevacizumab efficacy in metastatic colorectal cancer.
    Marisi, Giorgia
    Ulivi, Paola
    Scarpi, Emanuela
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Valgiusti, Martina
    Zoli, Wainer
    Amadori, Dino
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [7] Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer
    Tailor, Dhanir
    Resendez, Angel
    Garcia-Marques, Fernando Jose
    Pandrala, Mallesh
    Going, Catherine C.
    Bermudez, Abel
    Kumar, Vineet
    Rafat, Marjan
    Nambiar, Dhanya K.
    Honkala, Alexander
    Quynh-Thu Le
    Sledge, George W.
    Graves, Edward
    Pitteri, Sharon J.
    Malhotra, Sanjay, V
    CELL CHEMICAL BIOLOGY, 2021, 28 (08) : 1206 - +
  • [8] X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer
    Jiang, Yanhui
    Yang, Lewei
    Jiang, Ling
    Yu, Wenyan
    Jin, Zhongwen
    Qiu, Yeqing
    Liao, Yifeng
    Liu, Jihong
    Zhang, Hongyu
    FRONTIERS IN GENETICS, 2022, 13
  • [9] Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis
    Zhao, Yaqi
    Wu, Jie
    Li, Lan
    Zhang, Huibo
    Zhang, Haohan
    Li, Jing
    Zhong, Hao
    Lei, Tianyu
    Jin, Yan
    Xu, Bin
    Song, Qibin
    FRONTIERS IN GENETICS, 2022, 13
  • [10] Plasminogen activator inhibitor-1 RNA binding protein expression in epithelial ovarian cancer
    Koensgen, D.
    Mustea, A.
    Dahl, E.
    Klaman, I.
    Petschke, B.
    Suri, P.
    Lichtenegger, W.
    Sehouli, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 263 - 263
12345